Loading...
OTCMSHWGY
Market cap2.51bUSD
Jan 24, Last price  
2.54USD
1D
14.41%
1Q
1.60%
Jan 2017
2.83%
Name

Shandong Weigao Group Medical Polymer Co

Chart & Performance

D1W1MN
OTCM:SHWGY chart
P/E
41.56
P/S
6.29
EPS
0.44
Div Yield, %
2.09%
Shrs. gr., 5y
0.16%
Rev. gr., 5y
8.47%
Revenues
13.23b
-2.86%
407,823,000569,987,000786,926,0001,095,109,0001,514,367,0001,878,495,0002,462,557,0003,180,577,0003,689,115,0004,613,310,0005,277,827,0005,918,930,0006,730,340,0006,292,641,0008,808,861,00010,364,081,00011,345,252,00013,151,719,00013,619,007,00013,229,453,000
Net income
2.00b
-27.57%
65,888,000102,578,000182,603,000329,342,000482,394,000633,864,000799,072,0003,462,172,000996,486,000387,984,0001,084,948,0001,112,736,0001,105,933,0001,303,162,0001,472,935,0001,844,883,0002,086,783,0002,275,929,0002,764,093,0002,001,906,000
CFO
2.80b
+26.37%
17,440,000118,032,000176,547,000276,211,000437,482,000479,074,000523,511,000620,792,000806,031,000720,174,000711,219,0001,052,770,0001,053,139,0001,267,008,0002,219,196,0002,320,990,0002,696,608,0003,035,163,0002,214,574,0002,798,529,000
Dividend
Jul 22, 20240.053 USD/sh
Earnings
Mar 24, 2025

Profile

Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, and sale of single-use medical devices in the People's Republic of China. It operates through Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and Others segments. The company offers vascular and non-vascular access infusion devices, infusion sets, syringes, puncture needles, and specialized single-use clinical collection kits; wound sutures, wound healing dressings, and wound cleaning and nonvascular catheter supporting extracorporeal devices; and blood collection, storage, separation, and sterilization equipment. It also provides prefilled syringes and pre-filled flush syringes; blood collection and blood glucose testing devices; and general anesthesia consumables, local anesthesia consumables, anesthesia auxiliary consumables, ICU equipment, and open and minimally invasive surgical equipment. In addition, the company engages in the production and sale of orthopedic devices; tumor and blood vessel interventional instruments; implantation materials and artificial organs; medical PVC granules, plastic packing bags, and carton boxes; industrial automatic equipment and parts; molds; hemodialysis equipment; and type I, type II, and type III medical devices. Further, it is involved in the finance leasing and factoring business; wholesale of type I medical devices, surgical devices, and other disposal medical products; provision of asset management, enterprise consulting, enterprise management advisory services, as well as logistics and storage services, as well as export its products. The company offers its products under the Jierui, Wego Ortho, Yahua, Bangde, and Hai Xing brands. It serves hospitals, blood stations, and other medical units; and distributors. The company was incorporated in 2000 and is based in Weihai, the People's Republic of China.
IPO date
Feb 27, 2004
Employees
12,333
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
13,229,453
-2.86%
13,619,007
3.55%
Cost of revenue
11,011,490
10,596,243
Unusual Expense (Income)
NOPBT
2,217,963
3,022,764
NOPBT Margin
16.77%
22.20%
Operating Taxes
307,585
424,267
Tax Rate
13.87%
14.04%
NOPAT
1,910,378
2,598,497
Net income
2,001,906
-27.57%
2,764,093
21.45%
Dividends
(732,633)
(741,638)
Dividend yield
2.13%
1.28%
Proceeds from repurchase of equity
(36,530)
(70,496)
BB yield
0.11%
0.12%
Debt
Debt current
2,573,337
990,131
Long-term debt
1,723,248
3,634,666
Deferred revenue
76,736
Other long-term liabilities
499,505
37,001
Net debt
(4,934,337)
(4,091,119)
Cash flow
Cash from operating activities
2,798,529
2,214,574
CAPEX
(647,577)
(1,116,239)
Cash from investing activities
(1,388,592)
(2,568,963)
Cash from financing activities
(2,157,858)
(1,020,957)
FCF
1,472,797
761,162
Balance
Cash
7,333,313
7,357,615
Long term investments
1,897,609
1,358,301
Excess cash
8,569,449
8,034,966
Stockholders' equity
20,628,179
20,529,200
Invested Capital
20,092,078
19,644,776
ROIC
9.62%
13.81%
ROCE
7.74%
10.84%
EV
Common stock shares outstanding
4,518,901
4,526,649
Price
7.61
-40.64%
12.82
31.76%
Market cap
34,388,837
-40.74%
58,031,640
32.06%
EV
30,998,084
55,718,187
EBITDA
3,129,667
3,825,276
EV/EBITDA
9.90
14.57
Interest
272,971
191,401
Interest/NOPBT
12.31%
6.33%